Countries

Read all the (latest) blogs from:

Australia, Austria, Belgium, Bulgaria, China, Czech Republic, Denmark, EPC, Estonia, European Union, Finland, France, Germany, Hungary, Iceland, India, Ireland, Italy, Latvia, Lithuania, Netherlands, Norway, Poland, Portugal, Romania, Russia, Slovakia, Slovenia, Spain, Sweden, Switzerland, Turkey, Ukraine, United Kingdom, United States of America

European Union, Pharma, Pharmaceutical patent, Plausibility, Second Medical Use, SPC, United Kingdom

, (Bristows)/

On Friday 1 March 2019, Arnold J handed down his judgment in the patent dispute between Eli Lilly and Genentech regarding IL-17A/F antibodies*1. This lengthy judgment, which as the Judge observed: “was one of most complex patent cases I have ever tried”, is littered with interesting legal points. However, to many life sciences patent lawyers,…

Inventive step, Netherlands, Pharmaceutical patent, SPC, Validity

(Brinkhof)/

In nullity proceedings initiated by Accord Healthcare (“Accord”) the District Court of The Hague has held Shire-NPS Pharmaceuticals’ (“NPS”) patent EP 1 203 761, the basic patent for an SPC covering cinacalcet, invalid for lack of inventive step and declared the SPC null. In short, the court considered that the (selection of) cinacalcet provided no…

AI, EPO, EPO Decision, European Union

, (GJE Intellectual Property)/ /3 Comments

Today, in the decision T 0489/14 the EPO’s Boards of Appeal published their referral of three questions relating to computer implemented simulations to the Enlarged Board of Appeal. Referrals to the EPO’s Enlarged Board of Appeal do not come around often, referrals in the area of computer technology even less so. The purpose of referrals…

Case Law, European Union, SPC

(Clifford Chance)/

One has to have a lot of courage to accept the task of coordinating a book on Supplementary Protection Certificates (“SPCs”). The immense variety of the facts discussed in the numerous cases that have historically sparked the need for preliminary questions to the Court of Justice of the European Union (“CJEU”) on the interpretation of…

European Union, France, Germany, Netherlands, Pharma, SPC, TRIPS, TRIPs Agreement

, (Vossius & Partner)/

The fundamental question which types of products are amenable to SPC protection and which types of marketing authorizations allow the filing of SPCs has aroused much controversy in Europe, and reached a climax when the CJEU in its judgment Boston Scientific (C-527/17) of 25 October 2018 denied the grant of SPCs on the basis of…

EPC, Plant variety

/ /4 Comments

The European Patent Office and representatives of the 38 Member States organised a meeting last week of the Committee on Patent Law to discuss next steps following decision T 1063/18 of an EPO Board of Appeal on plant patentability. Representatives of the European Commission were present as observer. In its landmark decision of 5 December 2018,…

European Union, Germany, Unitary Patent, United Kingdom, UPC

/

The Federal Constitutional Court of Germany (BVerfG) intends to decide on the complaint against German ratification of the Unified Patent Court Agreement this year. The case (2 BvR 739/17) is on the 2019 decision list, which was published yesterday. It doesn’t come as a surprise. The UPCA case was on the 2018 list as well,…

Case Law, Infringement, United States of America

(Wolters Kluwer Legal & Regulatory US)/

A district court erred in granting summary judgment to the defending provider on the grounds that the asserted claims were invalid for lack of written description and were not infringed by the provider’s system. Case date: 14 February 2019 Case number: No. 17-2510 Court: United States Court of Appeals, Federal Circuit A full summary of this…